Internal medicine

Adverse effect

Prednisolone

Filgrastim

Hepatic encephalopathy

Gastroenterology

Surgery

Randomized controlled trial

Hepatorenal syndrome

Cirrhosis

Chemotherapy

Granulocyte colony-stimulating factor

Pegfilgrastim

Medicine

EClinicalMedicine

This phase II trial found no survival benefit at 90 days among subjects with AH who received pegfilgrastim+prednisolone compared with subjects receiving prednisolone alone.

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis